477 related articles for article (PubMed ID: 27402235)
1. Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial.
Eisen A; Ruff CT; Braunwald E; Nordio F; Corbalán R; Dalby A; Dorobantu M; Mercuri M; Lanz H; Rutman H; Wiviott SD; Antman EM; Giugliano RP
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27402235
[TBL] [Abstract][Full Text] [Related]
2. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial.
Giugliano RP; Ruff CT; Wiviott SD; Nordio F; Murphy SA; Kappelhof JA; Shi M; Mercuri MF; Antman EM; Braunwald E
Am J Med; 2016 Aug; 129(8):850-857.e2. PubMed ID: 26994510
[TBL] [Abstract][Full Text] [Related]
3. Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy.
Okin PM; Bang CN; Wachtell K; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
Circ Arrhythm Electrophysiol; 2013 Apr; 6(2):243-51. PubMed ID: 23403268
[TBL] [Abstract][Full Text] [Related]
4. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Rost NS; Giugliano RP; Ruff CT; Murphy SA; Crompton AE; Norden AD; Silverman S; Singhal AB; Nicolau JC; SomaRaju B; Mercuri MF; Antman EM; Braunwald E;
Stroke; 2016 Aug; 47(8):2075-82. PubMed ID: 27387994
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
Kato ET; Giugliano RP; Ruff CT; Koretsune Y; Yamashita T; Kiss RG; Nordio F; Murphy SA; Kimura T; Jin J; Lanz H; Mercuri M; Braunwald E; Antman EM
J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207971
[TBL] [Abstract][Full Text] [Related]
6. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.
Bergmark BA; Kamphuisen PW; Wiviott SD; Ruff CT; Antman EM; Nordio F; Kuder JF; Mercuri MF; Lanz HJ; Braunwald E; Giugliano RP
Circulation; 2019 Nov; 140(22):1792-1801. PubMed ID: 31597460
[TBL] [Abstract][Full Text] [Related]
8. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Link MS; Giugliano RP; Ruff CT; Scirica BM; Huikuri H; Oto A; Crompton AE; Murphy SA; Lanz H; Mercuri MF; Antman EM; Braunwald E;
Circ Arrhythm Electrophysiol; 2017 Jan; 10(1):. PubMed ID: 28077507
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
Magnani G; Giugliano RP; Ruff CT; Murphy SA; Nordio F; Metra M; Moccetti T; Mitrovic V; Shi M; Mercuri M; Antman EM; Braunwald E
Eur J Heart Fail; 2016 Sep; 18(9):1153-61. PubMed ID: 27349698
[TBL] [Abstract][Full Text] [Related]
10. Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results From the STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure).
Rao MP; Al-Khatib SM; Pokorney SD; She L; Romanov A; Nicolau JC; Lee KL; Carson P; Selzman CH; Stepinska J; Cleland JG; Tungsubutra W; Desvigne-Nickens PM; Sueta CA; Siepe M; Lang I; Feldman AM; Yii M; Rouleau JL; Velazquez EJ;
Circulation; 2017 Mar; 135(12):1136-1144. PubMed ID: 28154006
[TBL] [Abstract][Full Text] [Related]
11. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.
Steffel J; Giugliano RP; Braunwald E; Murphy SA; Mercuri M; Choi Y; Aylward P; White H; Zamorano JL; Antman EM; Ruff CT
J Am Coll Cardiol; 2016 Sep; 68(11):1169-1178. PubMed ID: 27609678
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction).
Aisenberg J; Chatterjee-Murphy P; Friedman Flack K; Weitz JI; Ruff CT; Nordio F; Mercuri MF; Choi Y; Antman EM; Braunwald E; Giugliano RP
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e003998. PubMed ID: 29748353
[TBL] [Abstract][Full Text] [Related]
13. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
Bohula EA; Giugliano RP; Ruff CT; Kuder JF; Murphy SA; Antman EM; Braunwald E
Circulation; 2016 Jul; 134(1):24-36. PubMed ID: 27358434
[TBL] [Abstract][Full Text] [Related]
14. The association between atrial fibrillation and sudden cardiac death: the relevance of heart failure.
Reinier K; Marijon E; Uy-Evanado A; Teodorescu C; Narayanan K; Chugh H; Gunson K; Jui J; Chugh SS
JACC Heart Fail; 2014 Jun; 2(3):221-7. PubMed ID: 24952687
[TBL] [Abstract][Full Text] [Related]
15. Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation.
Sharma A; Hijazi Z; Andersson U; Al-Khatib SM; Lopes RD; Alexander JH; Held C; Hylek EM; Leonardi S; Hanna M; Ezekowitz JA; Siegbahn A; Granger CB; Wallentin L
Circulation; 2018 Oct; 138(16):1666-1676. PubMed ID: 29871978
[TBL] [Abstract][Full Text] [Related]
16. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Washam JB; Stevens SR; Lokhnygina Y; Halperin JL; Breithardt G; Singer DE; Mahaffey KW; Hankey GJ; Berkowitz SD; Nessel CC; Fox KA; Califf RM; Piccini JP; Patel MR;
Lancet; 2015 Jun; 385(9985):2363-70. PubMed ID: 25749644
[TBL] [Abstract][Full Text] [Related]
17. Atrial fibrillation is associated with sudden cardiac death: a systematic review and meta-analysis.
Rattanawong P; Upala S; Riangwiwat T; Jaruvongvanich V; Sanguankeo A; Vutthikraivit W; Chung EH
J Interv Card Electrophysiol; 2018 Mar; 51(2):91-104. PubMed ID: 29332241
[TBL] [Abstract][Full Text] [Related]
18. The Cumulative Incidence of Stroke, Myocardial infarction, Heart Failure and Sudden Cardiac Death in Patients with Atrial Fibrillation.
Naser N; Kulic M; Dilic M; Dzubur A; Durak A; Pepic E; Smajic E; Kusljugic Z
Med Arch; 2017 Oct; 71(5):316-319. PubMed ID: 29284897
[TBL] [Abstract][Full Text] [Related]
19. Risk factor and prediction modeling for sudden cardiac death in women with coronary artery disease.
Deo R; Vittinghoff E; Lin F; Tseng ZH; Hulley SB; Shlipak MG
Arch Intern Med; 2011 Oct; 171(19):1703-9. PubMed ID: 21788534
[TBL] [Abstract][Full Text] [Related]
20. Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial.
Eisen A; Ruff CT; Braunwald E; Hamershock RA; Lewis BS; Hassager C; Chao TF; Le Heuzey JY; Mercuri M; Rutman H; Antman EM; Giugliano RP
J Am Heart Assoc; 2017 Jun; 6(7):. PubMed ID: 28666993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
